Experimental HCV Drugs
Experimental HCV Drugs
Merck Discontinues Development of Experimental Hepatitis C Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 12 October 2017 00:00
- Written by HIVandHepatitis.com
Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor grazoprevir, the NS5A inhibitor ruzasvir, and the HCV polymerase inhibitor uprifosbuvir. The second is a 2-drug combo containing ruzasvir and uprifosbuvir.
Coverage of the 2017 Harm Reduction International Conference
- Details
- Category: HIV Treatment
- Published on Wednesday, 31 May 2017 00:00
- Written by HIVandHepatitis.com
HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.
5/31/17
EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 22 April 2017 00:00
- Written by Keith Alcorn
A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side effects, Xavier Forns reported on behalf of the EXPEDITION-1 study investigators at the International Liver Congress this week in Amsterdam.
EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 01 May 2017 00:00
- Written by Liz Highleyman
Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.
EASL 2017: AbbVie Combination Cures Most People with Genotype 3 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 21 April 2017 00:00
- Written by Keith Alcorn
AbbVie's pangenotypic direct-acting antiviral combination of 2 drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV) infection, the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the EASL International Liver Congress this week in Amsterdam.
More Articles...
- Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections
- CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals
- Gilead and AbbVie Seek FDA Approval of Pangenotypic Hepatitis C Treatments
- AASLD 2016: Glecaprevir/ Pibrentasvir Effective for Hepatitis C Patients with Severe Kidney Disease
Web Design and Development by